Our Next Event:
Special Speaker Series: Treating HCV in a Recovery Setting
The goal of this session is to help clinicians and other service providers understand the regional and national picture of HCV infection in the population of people in recovery. For those seeking treatment for addiction in a medication-assisted treatment (MAT) program, medical professionals can also assist with a treatment regimen for the HCV infection utilizing a number of new treatment options.
Global Awareness. Local Impact.
CLA's mission is to promote disease awareness, prevention, education, advocacy, and research. Headquartered in Pittsburgh and with offices in Milwaukee, the Community Liver Alliance has grown to have a national presence while still holding true to a mission to invest in local communities and give voice to patients and providers.
News & Information
Dr. Hamza Yazdani 2022 CLA Research Grant Recipient On behalf of the Community Liver Alliance and its Board of Directors, we are pleased to announce
There is 80 to 100 million people in the USA that have Fatty Liver Disease and most do not even know they have it. Liver Disease does not discriminate. It affects any age, social economics and race. Liver cancer incidence rates have more than tripled since 1980, while the death rates have more than doubled during this time.
Ensure funding for COVID-19 and liver disease public health programs, research, vaccine dissemination; ensure that people living with liver disease are not disproportionately impacted and do not experience unnecessary or discriminatory health care or treatment disruptions.
Address inequities in the care of people impacted by liver disease, especially the excess incidence rate of liver cancer in black men in America.
Advance the U.S. NASH Action Plan, and ensure patients with liver disease perspectives are represented in relevant legislative packages: COVID-19, diabetes, and obesity.
Work with regulators to establish logical pathways to consistently approve therapies for liver diseases, particularly rare liver diseases.
Advocate for funding that ensures meaningful growth of vital liver disease research and the improving of liver health.
Urgently respond to the inequities that impact organ transplantation; modernize the U.S. Organ Donation system, improve care for transplant patients, and increase the number of available organs.
Increase support for hepatitis programs and raise awareness of viral hepatitis; advocate for the elimination of viral hepatitis .
Advance health care policies that reflect each person’s unique needs and drive access to personalized, patient-centric care.
Support policy solutions that curb patients’ health care expenses; advocate for the smoothing and capping of out-of-pocket costs in Medicare Part D.